Filing Flows › ANI Pharmaceuticals (ANIP) › Guidance & outlook

ANI Pharmaceuticals (ANIP) guidance and outlook

ANI Pharmaceuticals (ANIP) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $1.1B for FY2026; EBITDA $290M–$300M for FY2026; EPS $9.37–$9.71 for FY2026; Gross margin 60.3%–61% for FY2026. ANI Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 16 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• Our dedicated sales force is focused on the appropriate patient population through podiatry and primary care physicians, while our existing sales organization will continue to focus on appropriate acute gouty arthritis flare patients seen by rheumatologists and nephrologists.
• Importantly, the addition of Alimera expanded the reach of the ophthalmology sales team and we believe there will be significant overlap between high potential prescribers of Cortrophin Gel and the Retina Franchise.
• We plan to continue to expand our Rare Disease business, through a combination of organic growth and acquisitions.
• While we execute against our strategic initiatives that we believe will result in long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to expand our existing capabilities.
• We plan to strengthen our Generics and Other segment through continued investment in our research and development capabilities and increased focus on niche opportunities.
• Additionally, we plan to continue to seek opportunities to enhance our capab ilities through strategic partnerships and acquisitions of assets and businesses.
• This ability to manufacture a variety of differentiated products is a competitive strength that we intend to leverage in selecting products to develop and commercialize.
• When determining whether to develop or acquire an individual product, we review the current and expected market size and competitive environment for that product.
• In determining the potential profit of a product, we forecast our anticipated market share, pricing, competitive environment and the estimated cost to manufacture the products.
• When determining whether to develop or acquire a product, we research existing and expected competition.
• We seek to develop products for which we can obtain sufficient market share and may decline to develop a product if we anticipate significant competition.
• Essentially all of our Generics products face competition from other generic products, as do many of our Brands products, and we expect them to continue to face competition from generic products in the future.

ANI Pharmaceuticals' latest quarter

Questions

Did ANI Pharmaceuticals raise or lower its guidance?

ANI Pharmaceuticals (ANIP) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $1.1B for FY2026; EBITDA $290M–$300M for FY2026; EPS $9.37–$9.71 for FY2026; Gross margin 60.3%–61% for FY2026.

What does ANI Pharmaceuticals expect?

Our dedicated sales force is focused on the appropriate patient population through podiatry and primary care physicians, while our existing sales organization will continue to focus on appropriate acute gouty arthritis flare patients seen by rheumatologists and nephrologists. Importantly, the addition of Alimera expanded the reach of the ophthalmology sales team and we believe there will be significant overlap between high potential prescribers of Cortrophin Gel and the Retina Franchise. We plan to continue to expand our Rare Disease business, through a combination of organic growth and acquis

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.